Skip to main content
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1997 Nov;122(5):809–812. doi: 10.1038/sj.bjp.0701445

Antinociceptive activity of CP-101,606, an NMDA receptor NR2B subunit antagonist

Kana Taniguchi *, Katsuhiro Shinjo *, Mayumi Mizutani *, Kaoru Shimada *, Toshihisa Ishikawa *, Frank S Menniti *, Atsushi Nagahisa *,*
PMCID: PMC1565002  PMID: 9384494

Abstract

  1. The analgesic activity of CP-101,606, an NR2B subunit-selective N-methyl-D-aspartate (NMDA) receptor antagonist, was examined in carrageenan-induced hyperalgesia, capsaicin- and 4β-phorbol-12-myristate-13-acetate (PMA)-induced nociceptive tests in the rat.

  2. CP-101,606 30 mg kg−1, s.c., at 0.5 and 2.5 h after carrageenan challenge suppressed mechanical hyperalgesia without any apparant alternations in motor coordination or behaviour in the rat.

  3. CP-101,606 also inhibited capsaicin- and PMA-induced nociceptive responses (licking behaviour) with ED50 values of 7.5 and 5.7 mg kg−1, s.c., respectively.

  4. These results suggest that inhibition of the NR2B subunit of the NMDA receptor is effective in vivo at modulating nociception and hyperalgesia responses without causing the behavioural side effects often observed with currently available NMDA receptor antagonists.

Keywords: CP-101,606; NMDA receptor antagonist; nociception; hyperalgesia

Full Text

The Full Text of this article is available as a PDF (298.4 KB).


Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES